Department of Pharmaceutical Analysis, ISF College of Pharmacy, G.T. Road, Moga-142 001, Punjab, India.
Anticancer Agents Med Chem. 2022;22(5):812-820. doi: 10.2174/1871520621666210706150057.
Lurbinectedin was approved on June 15, 2020 by the Food and Drug Administration with the brand name ZEPZELCA as the first systematic approved therapy for patients having Small Cell Lung Cancer (SCLC).
In this review, an attempt is made to summarize different aspects of Lurbinectedin, including the pathophysiology, chemistry, chemical synthesis, mechanism of action, adverse reactions, and pharmacokinetics. Special attention is given to various reported clinical trials of lurbinectedin.
A comprehensive literature search was conducted in the relevant databases like ScienceDirect, PubMed, ResearchGate and Google Scholar to identify studies. After a thorough study of these reports, significant findings/data were collected and compiled under suitable headings. Important findings related to clinical trials have been tabulated.
Lurbinectedin is known to act by inhibiting the active transcription of encoding genes, thereby suppressing tumor-related macrophages with an impact on tumour atmosphere. Lurbinectedin has emerged as a potential drug candidate for the treatment of Small-Cell Lung Cancer (SCLC).
Lurbinectedin 于 2020 年 6 月 15 日获得美国食品药品监督管理局批准，商品名为 ZEPZELCA，成为首个获批用于小细胞肺癌（SCLC）患者的系统性治疗药物。
本综述旨在总结 Lurbinectedin 的不同方面，包括病理生理学、化学、化学合成、作用机制、不良反应和药代动力学。特别关注了 lurbinectedin 的各种已报道临床试验。
在 ScienceDirect、PubMed、ResearchGate 和 Google Scholar 等相关数据库中进行了全面的文献检索，以确定研究。对这些报告进行深入研究后，收集并汇编了相关标题下的重要发现/数据。对与临床试验相关的重要发现进行了制表。
已知 Lurbinectedin 通过抑制编码基因的活跃转录来发挥作用，从而抑制与肿瘤相关的巨噬细胞，对肿瘤微环境产生影响。Lurbinectedin 已成为治疗小细胞肺癌（SCLC）的潜在药物候选物。
